Avoplacel is under clinical development by Pluri and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Avoplacel’s likelihood of approval (LoA) and phase transition for Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) took place on 08 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.

In addition, the same event on 08 May 2021 increased Avoplacel’s LoA and PTSR for Bone Marrow Transplant Rejection.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Avoplacel Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Avoplacel overview

Avoplacel (PLXR-18) is under development for the treatment of acute radiation syndrome and incomplete hematopoietic recovery following bone marrow transplantation. The therapeutic candidate is an allogeneic product. The therapeutic candidate is administered through  intramuscular route. It is developed based on a three-dimensional technology platform which enables the conversion of human placental cells into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues.

It was also under development for the treatment of chemotherapy induced bone marrow hypoplasia, and aplastic anemia.

Pluri overview

Pluri, formerly Pluristem Therapeutics is a clinical-stage biotherapy company that focuses on the development of placental-derived cell therapies. The company’s placental expanded cells are adherent stromal cells that can be administered to patients without tissue or genetic matching. Pluri’s product pipeline includes PLX-PAD for critical limb ischemia, intermittent claudication, orthopedic conditions, pulmonary arterial hypertension and women’s health. The company’s PLX-Immune for kidney, colorectal, breast, lung, muscle, skin and liver cancers, PLX-R18 for hematological system and acute radiation syndrome. Pluri harnesses its proprietary 3D cell expansion platform technology for developing its cell therapies. It works in partnership with medical, pharmaceutical and academic institutions. Pluri is headquartered in Haifa, Israel.

Quick View Avoplacel LOA Data

Report Segments
  • Innovator
Drug Name
  • Avoplacel
Administration Pathway
  • Intramuscular
Therapeutic Areas
  • Hematological Disorders
  • Immunology
  • Toxicology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.